Table 3.

Changes in the 8 items of the norm-based Short-Form-36 scores from Pretreament to final follow-up.

		Pretreament	Treatment 4 weeks	Post treatment 1 month
PF	Moxibustion group	52.34	62.26	62.59	T-P: P>0.05 PT-P: P>0.05 PT-T: P>0.05
		±21.74	±19.70	±20.69
	Control group	54.52	61.38	64.26	T-P: P>0.05 PT-P: P>0.05 PT-T: P>0.05
		±20.79	±22.87	±21.29
		P>0.05	P>0.05	P>0.05
RP	Moxibustion group	25.78	33.87	31.03	T-P: P>0.05 PT-P: P>0.05 PT-T: P>0.05
		±32.68	±36.26	±33.84
	Control group	25.81	25.00	30.56	T-P: P>0.05 PT-P: P>0.05 PT-T: P>0.05
		±36.79	±36.60	±30.49
		P>0.05	P>0.05	P>0.05
BP	Moxibustion group	49.13	72.60	66.07	T-P: P<0.01 PT-P: P<0.01 PT-T: P>0.05
		±18.16	±15.43	±11.97
	Control group	50.24	62.31	59.17	T-P: P<0.01 PT-P: P<0.05 PT-T: P>0.05
		±19.38	±14.59	±12.83
		P>0.05	P<0.05	P<0.05
GH	Moxibustion group	43.44	56.55	52.76	T-P: P<0.01 PT-P: P<0.05 PT-T: P>0.05
		±17.62	±16.02	±13.34
	Control group	41.84	46.93	45.33	T-P: P>0.05 PT-P: P>0.05 PT-T: P>0.05
		±14.93	±15.51	±13.94
		P>0.05	P<0.05	P<0.05
VT	Moxibustion group	56.25	63.06	56.38	T-P: P>0.05 PT-P: P>0.05 PT-T: P>0.05
		±20.64	±15.20	±18.02
	Control group	52.90	55.86	57.41	T-P: P>0.05 PT-P: P>0.05 PT-T: P>0.05
		±16.67	±17.12	±14.10
		P>0.05	P>0.05	P>0.05
SF	Moxibustion group	67.58	78.23	79.31	T-P: P<0.05 PT-P: P<0.05 PT-T: P>0.05
		±21.73	±16.45	±16.80
	Control group	66.53	67.67	68.98.	T-P: P>0.05 PT-P: P>0.05 PT-T: P>0.05
		±21.50	±21.00	±19.11
		P>0.05	P<0.05	P<0.05
RE	Moxibustion group	45.83	59.14	41.38	T-P: P>0.05 PT-P: P>0.05 PT-T: P>0.05
		±44.60	±40.10	±39.50
	Control group	47.31	54.02	39.51	T-P: P>0.05 PT-P: P>0.05 PT-T: P>0.05
		±34.18	±38.23	±26.21
		P>0.05	P>0.05	P>0.05
MH	Moxibustion group	60.75	70.58	69.24	T-P: P<0.05 PT-P: P<0.05 PT-T: P>0.05
		±17.52	±17.14	±14.62
	Control group	59.61	57.10	55.41	T-P: P>0.05 PT-P: P>0.05 PT-T: P>0.05
		±18.02	±20.34	±17.32
		P>0.05	P<0.01	P<0.01